$592.44
1.51% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

argenx SE ADR Stock price

$583.62
-38.99 6.26% 1M
+33.62 6.11% 6M
-31.38 5.10% YTD
+186.51 46.97% 1Y
+259.21 79.90% 3Y
+450.31 337.79% 5Y
+560.62 2,437.48% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+16.53 2.91%
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization $35.46b
Enterprise Value $32.12b
P/E (TTM) P/E ratio 42.02
EV/FCF (TTM) EV/FCF 1,187.49
EV/Sales (TTM) EV/Sales 14.69
P/S ratio (TTM) P/S ratio 16.22
P/B ratio (TTM) P/B ratio 6.45
Revenue growth (TTM) Revenue growth 78.01%
Revenue (TTM) Revenue $2.19b
EBIT (operating result TTM) EBIT $-75.73m
Free Cash Flow (TTM) Free Cash Flow $27.05m
EPS (TTM) EPS $13.89
P/E forward 50.11
P/S forward 10.03
EV/Sales forward 9.09
Short interest 4.06%
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a argenx SE ADR forecast:

29x Buy
88%
4x Hold
12%

Analyst Opinions

33 Analysts have issued a argenx SE ADR forecast:

Buy
88%
Hold
12%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
2,186 2,186
78% 78%
100%
- Direct Costs 236 236
4% 4%
11%
1,950 1,950
95% 95%
89%
- Selling and Administrative Expenses 1,033 1,033
71% 71%
47%
- Research and Development Expense 975 975
29% 29%
45%
-58 -58
84% 84%
-3%
- Depreciation and Amortization 18 18
84% 84%
1%
EBIT (Operating Income) EBIT -76 -76
84% 84%
-3%
Net Profit 831 831
381% 381%
38%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
27 days ago
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the American Academy of Neu...
Neutral
Seeking Alpha
about one month ago
argenx SE (NASDAQ:ARGX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel D...
Positive
Seeking Alpha
about one month ago
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and the U.S. The sales outlook for 2025 looks strong, and I expect Vyvgart to once again exceed Street expectations. The pipeline catalyst calendar is light for 2025, and several far more important reado...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today